Rgenta Shows Early ACC Response Data for RGT-61159
WOBURN, Massachusetts, May 21, 2026 Rgenta Therapeutics announced positive preliminary results from its ongoing Phase 1a/b clinical trial evaluating...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WOBURN, Massachusetts, May 21, 2026 Rgenta Therapeutics announced positive preliminary results from its ongoing Phase 1a/b clinical trial evaluating...
